Phase Holographic Imaging’s closest competitor acquired for $320 million
Recently it was announced that Sartorius acquires Essen BioScience for $320 million in cash. Like Phase Holographic Imaging’s main product HoloMonitor®, Essen BioScience main product IncuCyte is a cell analyzer designed to be placed in a cell incubator to study the behavior of living cells over long time periods. Contrary to HoloMonitor, IncuCyte is based on conventional microscopy which in most cases requires that the cells are genetically modified or stained with toxic stains. For more information about the acquisition see Sartorius to Acquire Real-Time Live-Cell Analysis Pioneer and Leader Essen BioScience .
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.